Three human AML cell lines, Kasumi-1 (ATCC, Manassas, VA) with t(8;21) and heterozygous KIT N822K mutation, SKNO-1 (JCRB, Osaka, Japan) with t(8;21) and homozygous KIT N822K mutation, and OCI-AML3 (DSMZ, Brauschweig, Germany) with NPM1 mutation and DNMT3A mutation, were used in this study. Kasumi-1 cells were maintained in RPMI 1640 medium (ThermoFisher Scientific/GIBCO, Waltham, MA) containing 20% fetal bovine serum (FBS), SKNO-1 cells in RPMI 1640 medium with 10% FBS containing 10 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF; R&D systems, Minneapolis, MN), and OCI-AML3 cells in αMEM medium (GIBCO) containing 20% FBS. Cultures were grown at 37 °C in humidified atmosphere containing 5% CO2. These cell lines were authenticated (16-Markers STR) by the Food Industry Research and Development Institute, Hsinchu, Taiwan. Their genetic profiles were identical to reported information.
Cabozantinib-malate was purchased from Selleck Chemicals (Houston, TX) and dissolved in DMSO for storage at −20 °C. Cycloheximide (CHX), MG-132, Z-VAD-FMK, and puromycin were purchased from TargetMol (Boston, MA), Tocris Bioscience (Abingdon, UK), Abcam (Cambridge, MA), and GIBCO, respectively.
Cabozantinib-malate was purchased from Selleck Chemicals (Houston, TX) and dissolved in DMSO for storage at −20 °C. Cycloheximide (CHX), MG-132, Z-VAD-FMK, and puromycin were purchased from TargetMol (Boston, MA), Tocris Bioscience (Abingdon, UK), Abcam (Cambridge, MA), and GIBCO, respectively.